Delaware
|
000-32501
|
33-0827593
|
(State
or Other Jurisdiction of Incorporation)
|
(Commission
File
Number)
|
(I.R.S.
Employer Identification Number)
|
o |
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR
230.425)
|
o |
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
|
o |
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR
240.14d-2(b))
|
o |
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR
240.13e-4(c))
|
*
|
Exhibits
99.1 and 99.2 hereto are being furnished and shall not be deemed “filed”
for purposes of Section 18 of the Securities Exchange Act of 1934, as
amended, nor shall it be incorporated by reference into any registration
statement or other document pursuant to the Securities Act of 1933, as
amended, except as expressly set forth in such
filing.
|
CYTORI
THERAPEUTICS, INC.
|
|
Date: November
9, 2009
|
By: /s/ Christopher J.
Calhoun
|
Christopher
J. Calhoun
|
|
Chief
Executive Officer
|